Deep radiomics for prognostic prediction in locally advanced non-small cell lung cancer by leveraging OmicsMap-based image representation.

Patients with locally advanced non-small cell lung cancer (LA-NSCLC) exhibit heterogeneous prognoses despite receiving standard treatments, highlighting the need for more reliable prognostic biomarkers. This study aims to develop and validate OmicsMap model, a deep radiomics biomarkers derived from computed tomography images for the prediction of progression-free survival (PFS) in LA-NSCLC patients.We retrospectively analyzed data from 329 LA-NSCLC patients who underwent definitive radiotherapy. The cohort was randomly divided into development (= 220) and independent testing set (= 109). The prognostic signature was derived from integrated radiomics features extracted from both the primary tumor and involved lymph nodes, and inter-patient radiomics feature interactions. To achieve this, high-dimensional radiomics data from all patients were transformed into structured two-dimensional representations, termed OmicsMap, wherein radiomics feature interactions were encoded within the pixelated configuration. Deep radiomics features from the OmicsMaps were then extracted using a convolutional neural network for prognostic prediction. Model performance was evaluated by time-dependent area under the receiver operating characteristic curves area under the curve (AUC). Kaplan-Meier curves were plotted and hazard ratios (HR) were calculated via Cox proportional hazards model.The OmicsMap model achieved time-dependent AUCs of 0.76, 0.78 and 0.76 at 1, 2 and 3 years in the independent testing set, significantly outperforming the clinical model (AUC: 0.57, 0.57, 0.64;< 0.05). The proposed model improved predictive discrimination with 7.69% increase in C-index over conventional radiomics approaches. It effectively stratified patients into high-risk and low-risk subgroups for both PFS (< 0.001, HR = 0.380) and overall survival (= 0.0021, HR = 0.525) in the testing set.The proposed OmicsMap model provides a novel paradigm for enhancing prognostic prediction in patients with LA-NSCLC. By improving risk stratification, the framework may help inform clinical decision-making and support future efforts toward more individualized management strategies.